|
FDA Considers Guidance on Ad Claims Comparing Competing Drugs
A sharp increase in exaggerated or misleading comparative claims in drug advertisements has the FDA analyzing the issue and considering guidance to help stop the violations.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives